AbbVie stock moves up amid positive EMA recommendations for key drugs: weekly review

Traders Union
All News
Financial News
AbbVie gains 2.52% over the week

Highlights

ABBV holds a bullish technical setup with price trading above medium- and long-term moving averages, attracting active buyers.
Momentum indicators are mixed, with some signals showing short-term buyer strength while others suggest lacking trend conviction.
ABBV is expected to trade between $209.25 and $222.24 next week, with a downside bias due to low probability of sustained upside breakout.

European regulatory progress boosts sentiment and sector exposure this week

AbbVie received positive recommendations from the European Medicines Agency for two of its products, Boey in aesthetics and MAVIRET for treating acute hepatitis C, including use in children as young as three years old. These opinions by the EMA’s Committee for Medicinal Products for Human Use pave the way for upcoming regulatory approvals in up to 30 European countries. The decisions are likely to expand the company's exposure in both the aesthetics and virology markets across Europe.

Mixed weekly momentum as bullish trend meets neutral technical signals

On the weekly (W1) technical chart, ABBV maintains a bullish structure, with the price above both the MA-20 and MA-50, and well above the MA-200, confirming medium- and long-term uptrends. Weekly momentum, however, remains mixed: the MACD is giving a sell signal while the ADX is neutral, pointing to a lack of clear directional strength. The RSI (W1) signals a buy, whereas Stochastic RSI and CCI print neutral, suggesting little indication of short-term overbought or oversold conditions. Bull/Bear Power remains in the overbought zone, reflecting ongoing short-term buyer dominance, but this is offset by the neutral Awesome Oscillator. Support on the weekly chart is found near MA-20 and MA-50, while resistance is situated at $222.24.

Range-bound outlook favored as mixed indicators limit breakout potential

For the next 5 trading days, ABBV is expected to trade within a $209.25 to $222.24 range, reflecting recent volatility and mixed weekly momentum signals. The likelihood of further upside is modest, with only 1 out of 4 major weekly indicators signaling Buy or Strong Buy, suggesting that a pullback toward dynamic supports near $209 is more probable. Should weekly buyers overcome resistance, a test of $222 could be seen, but the baseline scenario favors range-bound action as buyers and sellers vie for control.

Earlier, analysts noted that AbbVie’s shares faced ongoing technical headwinds despite resilient business fundamentals, resulting in a cautious outlook for near-term upside. The latest rebound above key weekly averages, alongside significant regulatory milestones in Europe, suggests buyers may have reclaimed momentum, making resistance at $222 the critical level to monitor for confirmation of a sustained bullish shift.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.